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Introduction 
Natural products continue to be an important source of medicines and drug templates.  This is likely 
due to the vast chemical diversity of natural products, which increases the probability of finding 
structurally distinct “’lead compounds’” for different targets and diseases (Gu et al., 2013). This 
diversity is, in part, reflected by the size of natural product libraries that have been created, such as 
Supernatural II (http://bioinf-applied.charite.de/supernatural_new/index.php?site=home ), which 
has 325,508 different natural compounds (Banerjee et al., 2015). 
It has been estimated that approximately a third of all FDA-approved drugs over the past 20 years 
are based on natural products or their derivatives (Thomford et al., 2018).  Considering the number 
of natural compounds that may be available for research, the potential for discovery of novel 
biological activity that might be relevant for human or veterinary therapeutics is substantial. For 
example, the Dictionary of Natural Products has thus far recorded ~200,000 plant secondary 
metabolites, including about 170,000 unique structures (Harvey et al., 2015) and the open access 
initiative (led by the U.S. National Cancer Institute) with libraries of ~80,000 plants, ~20,000 
marine samples and ~ 6,000 microbes, estimates that ~1,000,000 distinct fractions will be derived 
over the next 3-4 years 
(https://dtp.cancer.gov/organization/npb/npnpd_prefractionated_library.htm).   
In addition to the well-established role in drug discovery, natural product pharmacology is relevant 
in the context of the use of dietary supplements, which are part of the vast and nebulous 
nutraceutical market and includes vitamins, amino acids, proteins, minerals, fibres, plant extracts 
and natural compounds (Andrew and Izzo, 2017). Due to a lack of rigorous regulation in many 
countries, dietary supplements can be marketed without clinical evidence of efficacy and with 
uncertain composition (Andrew and Izzo, 2017). Despite this shortcoming, demand for dietary 
supplements continues to grow (Williamson et al., 2020). Herbal dietary supplement sales in the 
United States experienced record growth in 2018 and consumers spent $8.842 billion on herbal 
supplements across all market channels (Smith et al., 2018). Furthermore, traditional medicine 
(such as Ayurveda, Traditional Chinese Medicine, Unani, and many others) not only continue to 
form an integral part of treatment within certain cultures but have also entered Western culture 
(Williamson et al., 2020). 
Considering the above, it is not surprising that BJP receives many submissions that focus on the 
pharmacology of specific natural products. For the great majority of natural product papers 
published in BJP, the Authors include final summative statements that propose a naturally-
occurring molecule for further clinical development or immediate use as a dietary supplement in the 
nutraceutical market. Many of these papers also identify novel drug targets, elucidate the mode of 
action, discover lead compounds as well as offering potential natural product repositioning (see 
Table 1 for a non-exhaustive list). All of these issues are highly relevant for BJP and offer novel 
pharmacological approaches to discovery science as well as potential therapeutics. 
However, the acceptance rate of “’natural product’” submissions in BJP is lower than for 
manuscripts related to other topics (approximately 11% vs 22% acceptance rate). The editors of BJP 
consider natural product research as a fundamental field of pharmacology and seek to publish 
research in this area of the highest quality and with excellent reproducibility. In order to support 
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authors in understanding the expectations for natural product research manuscripts, we (the Senior 
Editorial team) have written this Editorial with the aims of  i) providing clear advice to authors 
regarding the minimum standards required for publication in BJP so as to maximize the possibility 
of acceptance of such articles submitted to the Journal (and possibly elsewhere); ii) to help BJP 
Editors and reviewers in focusing on simple - but important – points that are often overlooked 
during the review process, but essential to support transparency and reproducibility of 
pharmacological natural product research. 
  
1. BJP has a specific pharmacological focus  
BJP does not publish papers that are limited to identification of natural products. Isolation, 
purification, elucidation of structure and semi-synthesis of chemical compounds are considered only 
in a context in which a robust, deep, and detailed pharmacological analysis and mechanism for 
biological activity attributed to the natural product are provided. As an example, in a BJP paper 
published by Yin and colleagues in 2015 the authors provided evidence of the synthesis of a 
previously isolated metabolite from Danshen (Salvia miltiorrhiza), which was identified by using 
mass spectrometry and proton and carbon nuclear magnetic resonance spectra. This information 
was provided along with detailed pharmacological analysis, which revealed that the natural 
compound prevented isoprenaline-induced cardiac fibrosis through inhibiting a NOX2/ROS/p38 
pathway (Yin et al., 2015). Identification of the possible mechanism of action of the natural product 
is mandatory for publication in BJP. 
 
2. BJP will publish studies on mixtures of compounds (such as herbal extracts) but only when 
accompanied by identification of the active component 
BJP only considers papers that describe studies on purified active compounds; in such cases, the 
purity of the compound, as well as major impurities, must be reported. BJP does not consider papers 
on mixtures of compounds (such as herbal extracts alone) unless the manuscript also demonstrates 
that any activity evidenced is reproduced by a purified component of that extract. In some cases, the 
activity of an extract or mixture may be due to additive or synergistic activities of multiple 
compounds.  If this is the case, then this finding should be shown by combining purified 
constituents and demonstrating functional activity that replicates the mixture. Overall, it is 
important to define which and how compound(s) of the extract is (are) contributing to the 
pharmacological activity. 
 
As an example in which evaluation of an extract was followed by a detailed pharmacological 
analysis of the main active ingredient, a BJP paper reported that a number of distinct Chinese herbal 
medicine extracts increased the expression of uncoupling protein 1 (UCP1) in isolated adipocytes 
(Nie et al., 2018). The authors found that extracts from the Chinese plant Astragalus 
membranaceous had the greatest activity in this respect, then isolated and purified the components 
of that extract (with data from HPLC identifying the constituents) and identified the isoflavone 
formononetin as the chemical component responsible for the functional activity. Subsequently, the 
authors elucidated the pharmacological profile and the mode of action of formononetin, using a 
number of  pharmacological and molecular approaches, and showed that it binds PPARγ, reduces 
weight gain and increases energy expenditure in obese mice.   
 
However, the following are some exceptions in which BJP may consider studies on herbal extracts 
whereby discovery of the active components as potential therapeutics is not the aim of the study:  
 
i) BJP will consider studies on chemically-characterized herbal extracts if a considerable 
clinical interest exists. An example is the case of  the Cannabis-derived medicines, which are used 
for the treatment of spasticity associated with multiple sclerosis and for the treatment of paediatric 
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epilepsies. Whalley and colleagues evaluated the effect of diverse Cannabis extracts, with different 
concentrations of Δ9-tetrahydrocannabinol (euphoric, convulsant) and cannabidiol (non-euphoric, 
anticonvulsant), on experimental seizures in animals (Whalley et al., 2019). The authors discovered 
that the controversy surrounding the reported proconvulsant effects of Δ9-tetrahydrocannabinol was, 
in part, fuelled by major species differences in cannabinoid signalling and that these differences 
should be taken into consideration when seeking to better understand this potentially serious side 
effect. 
ii) BJP will consider studies aimed at identifying the pharmacokinetic profile of single 
constituents after the administration of chemical-characterized, clinically well-studied extracts. For 
example, Chen and colleagues delineated the pharmacokinetics of flavonols and terpene lactones 
after dosing standardized Ginkgo biloba leaf extracts to rats via systemic or oral administration 
(Chen et al., 2013). 
 
3. BJP requires full disclosure about extract and natural product preparation  
Details regarding extracts must be provided: the part of the plant/marine entity or microbe used, the 
method of extraction, the yield of dried extract as a percentage weight of the starting fresh or dried 
material as well as type and concentration of extraction solvent.  For all starting materials, the 
formal biological name should be given from which the extract is derived. The scientific name 
(including the family) should be used as per the Integrated Taxonomic Information System website 
and should be in the binomial format composed of the genus and species.   
 
The source of the product (i.e. country and region) should be stated. For rare organisms and all 
plants a logged sample/voucher specimen stored within an accessible database in a recognised 
institution must be provided to enable others to access the sample and conduct analyses (Culley, 
2013). Samples stored in personal and private stores and not available to other scientists are not 
considered acceptable 
 
To ensure reproducible pharmacological activity, the extract must be chemically-characterized (e.g. 
by HPLC fingerprint, metabolomics) and the content of marker compound(s) measured with 
validated analytical methods. For extracted compounds, phytochemical characterization, purity (%) 
and methods used to determine compound identity and purity must be stated. Most compounds 
should be tested at high purity (95-99%). However, in some instances this may be difficult to 
achieve and if so, authors are required to provide a clear description of the other constituents and 
explain how these other components have been accounted for in the analyses.  A figure that shows 
the structure of the extracted compound must be included. For commercially available compounds, 
the name of the supplier must also be included. Overall, reproducibility of findings is facilitated by 
the full disclosure of source of plant/tissue (provenance) and extraction process.  To enable the 
latter, BJP has no word count restriction on methods. All extracts used must be available to the 
readership either through an open access facility or from the authors. 
 
4. BJP requires that the effects of the vehicle employed must be tested and reported 
Many compounds of natural origin are not easily soluble in water or saline and, hence, they may be 
dissolved in organic solvents, such as dimethyl sulphoxide (DMSO), ethanol, vegetable oils 
(sesame oil, corn oil) or ethanol. Unfortunately, many organic solvents, at relatively low 
concentrations, may effect cell lines or isolated tissue and interfere with outcomes of in vivo 
investigations. Cell-based assays are often intolerant to solvent concentrations of greater than 1% 
(Hughes et al., 2011). For example, DMSO, which is probably the most frequently used organic 
vehicle, exerts a number of pharmacological actions including differentiation of malignant cells, 
antioxidant and antibacterial activity, vasodilatation and smooth muscle relaxation as well as 
behavioural and in vivo cardiovascular effects (Jacob and Herschler, 1986; Castro et al., 1995; 
Parisi et al., 2010). Therefore, vehicles should be used at the lowest possible concentrations 
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ensuring solubilization and their effect on the responses under study must be clearly reported. 
Inadequate consideration of the effects of the vehicle can lead to incorrect judgement regarding 
intervention effects. A recent example of incomplete consideration of vehicle effects has occurred 
in the field of cardiovascular therapeutics with marine lipids. A substantial literature has reported 
positive effects of marine lipids upon circulating triglyceride levels; raised triglycerides correlates 
with worse outcome in terms of cardiovascular events (Sarwar et al., 2007). A large prospective 
study assessing the impact of icosapent ethyl in patients with raised triglyceride levels (REDUCE-
IT) recently published its results (Bhatt et al., 2019). In this study the investigators assessed whether 
the refined marine lipid improved outcome for patients at risk.  The results suggested that in 
comparison to the placebo, a mineral oil that mimicked the color and consistency of icosapent ethyl, 
icosapent ethyl  reduced the cumulative incidence of cardiovascular events.  However, for the 
subjects enrolled in REDUCE-IT, low-density lipoprotein cholesterol (LDL-C) was 75 mg/dL at 
baseline (on statins). In the active-intervention group, the LDL-C rose 2 mg/dL, whereas in the 
placebo (mineral oil) group it rose 7 mg/dL, for a net increase in LDL-C of 5 mg/dL in the latter. 
This level of LDL-C is known to be associated with an increase of events and thus raised the 
possibility that the icosapoent ethyl might be simply preventing the detrimental effects of another 
component of the fish oil.  
 
There are also instances when in order to reach high concentrations of the compound under 
investigation (e.g., to construct a full concentration-response curve in agonist/antagonist studies), 
the vehicle can affect the response under study. In such cases, concentration-response curves for 
both the vehicle and the compound under investigation must be compared and shown. As an 
example, in BJP, Thomas and colleagues reported that the plant-derived compound cannabidiol 
displayed high potency as an antagonist of CB1 and CB2 receptors. The [35S]GTPγS binding assay 
was used to determine both the efficacy of cannabidiol and the ability of cannabidiol to antagonize 
cannabinoid receptor agonists at the mouse CB1 and the human CB2 receptor. In this assay, the 
concentration-response curve related to the vehicle (DMSO) was clearly shown in figures, in 
comparison with the curve related to the effect of cannabidiol in the vehicle (Thomas et al., 2007) 
 
5. BJP requires that a positive control is included 
A further issue in the study of natural products is the need for testing a positive control, i.e. 
comparison of the natural compound under investigation with a well validated drug effective in the 
selected pharmacological model. Unfortunately, in many published papers, this requirement is 
ignored. Virtuous examples in BJP are below: 
 
i) dexamethasone (s.c. treatment) and budesonide (aerosol treatment) were used as positive 
controls in evaluating the effect of the sesquiterpene α-humulene in an experimental model of 
airways allergic inflammation (Rogerio el., 2019). 
ii) tirofiban (an antiplatelet drug belonging to the class of glycoprotein  IIb/IIIα antagonists) 
was used as a positive control in investigating the protective effect of the anti-thrombotic agent 
anfibatide (a glycoprotein Ib antagonist derived from snake venom) in a murine model of brain 
ischaemia (Li et al., 2015). 
 
The comparison should also consider the size of the effect and the possible clinical relevance. There 
are cases in the literature in which, although a conventional statistical significance is reached, the 
size of the effect is insignificant in the context of the disease target. As highlighted in a previous 
BJP editorial, a “10% change may be very relevant in some gene expression studies, whereas a 90% 





6 BJP requires that the concentration used in vitro is appropriate for further pharmaceutical 
development  
Cells in culture or isolated organs are often used in pharmacological research to screen new 
compounds isolated from natural sources and to delineate their mode of action. A major advantage 
of in vitro studies is that it is possible to test a broad range of  high drug concentrations that cannot 
be reached in vivo. Whilst we do not prohibit the assessment of only high concentrations of active 
compounds in in vitro studies with few possibilities of in vivo application or inappropriate for 
further pharmaceutical development and drug discovery these are discouraged (Heinrich et al., 
2020). There are many examples in the natural product literature in which high concentrations have 
been used to evoke a pharmacological effect that is then associated with claims for a therapeutic use 
(Gertsch, 2009; Butterweck and Nahrstedt, 2012). It has been argued that the molecular structures 
of natural compounds are such that they facilitate interaction with proteins and hence, at high 
concentrations, natural compounds are likely to produce unwanted effects (Gertsch, 2009). Indeed, 
testing compounds targeting specific proteins (e.g. receptors, enzymes) at concentrations that 
exceed by 10-fold the IC50 or Ki for the molecular target increases the possibility of introducing off-
target actions (Smith and Houghton, 2013; Liston and Davis, 2017). 
 
Unfortunately, there are no accepted limits beyond the cut-off concentrations commonly used in the 
pharmaceutical industry (EC50 < 10 µM) (Gertsch, 2009). Compound screening assays for hit 
discovery are typically run at 1-10 µM compound concentration (Hughes et al., 2011). A recent 
guide authored by editors of journals specialized in natural products research suggests that 
concentrations higher than 30-50 µM should not be used (Heinrich et al., 2020).  BJP does not have 
a policy restricting concentration other than that the concentrations tested are achievable in vivo 
without causing unwanted biological effects (off or on target). For the evaluation of certain 
pharmacological activities, some suggestions are reported elsewhere. For example, antimicrobial 
activity is believed to be meaningful at concentrations below 25 µM (Cos et al., 2006). For 
antiproliferative/cytotoxic studies, it is recommended that compounds have selectivity and are not 
“anti-life” (Heinrich et al., 2020). In such studies, a comparison between the effect on tumors vs 
healthy cells is recommended.  If the aim of the study is to identify the constituent responsible for 
effects of diet, the effects of the compound must occur at concentrations commensurate with those 
achieved from dietary consumption. 
 
In general, it may be wise to ask the following question: “can the concentrations used in vitro be 
present in the blood and tissue/cellular target after the administration of a therapeutic dose of the 
compound under investigation”? The answer to this simple question requires knowledge of the 
pharmacokinetic profile of the compound under investigation.   
 
An interesting study that investigated the in vivo relevance of a concentration used in vitro was 
recently published in BJP (Yeo et al., 2017). The authors found that the dietary polyphenol 
isorhapontigenin inhibited interleukin-6 (IL-6) release from airway epithelial cells. On the basis of 
pharmacokinetic data obtained in rats in vivo, the authors postulated that the concentration used in 
vitro can be reached following oral dosing of isorhapontigenin and that at least 30% inhibition of 
IL‐6 release can be attained through a single oral dose of isorhapontigenin (Yeo et al., 2017). 
 
It is important to note that the compound under investigation might be a pro-drug - or, more 
generally, may be metabolized in vivo before the absorption phase and, hence, the results obtained 
in vitro could be misleading. This is common for natural products since many plant compounds 
exist in nature as glycosides, which are generally deglycosylated by intestinal microbiota, making 
the non-sugar portion available to be absorbed. 
 
7. BJP requires that the dose used in vivo is translationally relevant  
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Extrapolation of dose from animal experiments to the human situation may be a difficult task (Nair 
and Jacob, 2016).  In addition to body weight, a number of variables should be considered, 
including body surface area, pharmacokinetic parameters (clearance, volume of distribution) and 
inter-species differences in the pharmacodynamics. A comprehensive analysis of the principles of 
interspecies dose extrapolation is beyond the scope of this Editorial. Readers can refer to a paper 
published some years ago in BJP (Sharma and McNeill, 2009).   
 
Allometric scaling of drug doses from preclinical experiments has been frequently used to predict 
the dose for single dose studies for first-in-human trials. This empirical approach is based not only 
on body weight, but on the normalization of dose to body surface area (mg/m2). Tables created from 
FDA guidelines, available elsewhere (Sharma and McNeill, 2009; Nair and Jacob, 2016), represent 
a practical tool for the conversion of doses between animals and humans. 
 
Unfortunately, interspecies dose conversion is very rarely considered. By analyzing BJP papers on 
natural products published in recent years, dose extrapolation is required in three main situations:  
 
i) to promote the compound under investigation as a candidate for clinical development or as 
a dietary supplement (extrapolation from animals to humans).  
ii) to investigate the mechanism of action of natural drugs or already marketed dietary 
supplements (extrapolation from humans to animals).  
iii) to unravel the possible beneficial (or detrimental) effect of a natural compound in the 
context of a diet or  an ingested food.  
 
An example in which the dose has been correctly extrapolated from humans to animals can be 
found in BJP (Simeoli et al., 2017). The authors compared the effect of the dietary supplement 
butyrate (a postbiotic compound) with a more palatable butyrate-releasing derivative in a murine 
model of colitis. The daily dose (20 mg/kg) used in the mouse is convertible to a human equivalent 
dose (Nair and Jacob, 2016) of 113.4 mg, for an adult human subject weighing 70 kg. This dose is 
in the range or even less than the common dose of butyrate used in humans. 
 
Conversely, one of the examples where dose ranges of activity do not match dietary approaches has 
been given by resveratrol, which, in an article published in Nature some years ago, was found to 
improve survival of mice on a high-calorie diet (Baur et al., 2006). By extrapolating the dose used 
in animals by using allometric scaling (Nair and Jacob, 2016), which considers body weight and 
surface area, the results suggest that a person would have to drink 55 bottles of wine per day.   
 
In summary, dose ranges in animal experiments must be relevant from a preventive or therapeutic 
viewpoint and evidence supporting this must be provided. In general, multiple doses are generally 
recommended (in the context of compliance with the 3Rs—need to spelled out for readers). Single 
doses are accepted in complex pharmacological models only.  
 
8. BJP requires that the route and timing of administration are appropriate  
The route of administration plays a fundamental role in experimental design using animals. In 
traditional medical systems, most herbal remedies are administered orally, for example in the form 
of infusions or decoctions (Abdul and Huang, 2015). Similarly, natural products available in the 
market are generally dispensed in pharmaceutical forms for oral use. Therefore, the oral route of 
administration is preferred in pharmacological translational experiments related to natural products, 
especially when the study aims:  
(i) to promote  the compound under investigation as a dietary supplement;  
(ii) to explain the possible beneficial effect of an ingredient found in the diet; or 
(iii) to validate the traditional use of a natural compound (ethnopharmacological studies). 
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Thus, parenteral administration, such as s.c., i.p. or i.v. has little value in the context of the dietary 
supplements market and it should be limited only for studies related to conventional drug discovery. 
 
In addition to traditional oral/parenteral dosing methods, compounds under investigation can be 
incorporated into the diet, as for example in a study published in BJP that assessed the impact of 
dietary supplementation for 2 months with the plant product quinic acid on glucose metabolism 
(Heikkilä et al., 2018). In order to determine how much compound needs to be mixed into the diet, 
it is essential to know key pieces of information, including the daily dose that the researcher aims to 
give to animals,  the weight and usual daily food intake of the animal (Ricci, 2012). The inclusion 
of compounds into the diet has a precise significance when the study aims to unravel the relevance 
of a specific natural compound in the context of a diet. 
 
The timing of drug administration (preventive vs curative) is also important. Compounds under 
study should not be given before administration of an agent used to induce an experimental disease, 
unless the authors are evaluating a possible candidate for prevention. For settings in which the goal 
is to cure rather than to prevent, compounds should be given after administration of the insult. 
 
9. BJP requires that the potential toxicity of the compound under evaluation is considered  
Many drugs fail in the clinic because they are not safe (Hughes et al., 2011). Thus, at the preclinical 
level, the determination of safety is as important as the proof of efficacy, both for submission to 
clinical trial as well as for promoting a natural compound as a food supplement. As a 
pharmacological journal, we do not ask for in vivo toxicology, but, whenever possible, authors are 
encouraged to provide information on the toxicity of the product under evaluation. For example, if a 
study is solely performed in vitro, some assessments of in vitro toxicity, such as cell viability or 
mitochondrial function are advised. For in vivo studies, measures of potential toxicity could include 
assessment, for example, of liver, renal or cardiac function. For selected pharmacological activities, 
such as antiproliferative/cytotoxic activity, the authors should show that extracts or compounds 
have selectivity vs cancer cells and are not “anti-life” drugs (Heinrich et al., 2020). Ideally, a 
comparison of the effect between cancer and healthy cells (if available), especially when the effect 
is observed at high concentrations, should be provided.  
Finally, authors are also encouraged to review the literature to verify if toxicological information 
has already been reported. For example, Romano and colleagues found that the plant cannabinoid 
cannabichromene ameliorated experimental colitis at a dose which was more than 100-fold lower 
than the subacute LD50 dose reported in the literature (Romano et al., 2013). 
   
 
10. BJP guidelines must be adhered to 
Since 2016 the BJP has adopted a series of guidelines to support transparency and reproducibility.  
A major initiative has been the publication and implementation of guidelines related to design and 
analysis of experiments. The journal has published two editorials on this topic describing the 
requirements for submissions to the journal (Curtis et al., 2015; Curtis et al, 2018). Key issues 
highlighted in these guidelines include a need for blinding and randomisation in design, ideally 
evidence of sample size determination and a requirement for minimum n values of 5 prior to 
subjecting datasets to comparative statistical analysis. For all studies involving animals, animal 
tissues or primary cultures, authors must address issues raised in the BJP editorial “Implementing 
guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in 
BJP (McGrath and Lilley, 2015). Authors are encouraged to read BJP editorials on data presentation 
and sharing (George et al., 2017; George et al., 2019) as well as on the goals and the practicalities 
of immunoblotting and immunohistochemistry (Alexander et al., 2018). Checklists covering these 
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requirements are available on BJP website 
(https://bpspubs.onlinelibrary.wiley.com/hub/journal/14765381/declaration_english) 
 
Finally, BJP now requires sex to be considered as a variable for all experimental reporting 
(Docherty et al. 2018). BJP editors recommend that all experiments (in vitro, in vivo, and ex vivo) 
should include both sexes, unless there is a specific justification not to do this. 
 
Conclusions 
This Editorial illustrates major requirements that authors should consider before submitting articles 
to BJP (see Table 2 for Authors checklist). It also highlights some common shortcomings in natural 
product pharmacological research, which could be prevented if experiments have appropriate 
planning and experimental design. 
 
BJP is a leading journal in the pharmacological field, in which important new advances are 
published and thus novelty is a major determinant of acceptance for publication. Studies showing 
the effect of natural products, without a substantial investigation into the mode of action, are not 
considered. Articles limited to repetition of well-known data or that report similar pharmacological 
activities of similar chemical compounds are generally not suitable for BJP.  
 
The editors of BJP recognise the wealth of opportunity for therapeutics that comes from the natural 
world and are keen to publish excellent natural product pharmacology that advances understanding 
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Table 1. Examples of articles on natural products published in the BJP 
 
Article type Example in the BJP Reference 




 Betulic acid, via FXR activation, attenuated non-alcoholic 
fatty liver disease (NAFLD) in an animal model of hepatic 
steatosis. 
The Authors conclude that “Our data suggest that the 
effects of Betullic acid may be used to develop a novel 
therapy for the management of NAFLD” 
 
Gu et al., 
2018 
Papers promoting a 
phytochemical for 
immediate use in 
humans as a dietary 
supplement 
 β-Caryophyllene protects against experimental alcoholic 
steatohepatitis    
The Authors conclude that “Our study may have immediate 
translational potential in liver disease as BCP is an FDA 
approved food additive for humans” 
Varga et al., 




the effect of a 
phytochemical in the 
context of a diet 
Resveratrol exists in high quantities in certain foods such as 
muscadine grape and red wine (Durazzo et al., 2019). A BJP 
paper found that resveratrol, incorporated into the diet, at a 
dose able to achieve relevant circulating resveratrol levels, 
protected against bone loss. 
Zhao et al., 
2012 
Paper providing the 
pharmacological 
basis able to justify 
the use of a dietary 
supplement  in 
humans 
 
Palmitoylethanolamide (PEA) is a food supplement 
marketed to alleviate inflammatory bowel disease, even in 
absence of clinical trials substantiating this claim. 
A BJP paper found that oral administration of PEA is 
therapeutic in a murine model of colitis. The Authors believe 
that the results could justify the use of PEA for IBD in 
humans 
 
This example is reminiscent of the ethnopharmacological 
approach, i.e.  the study of natural medicines that have been 
traditionally used by ethnic groups. Ethnopharmacology uses 
the “reverse pharmacology approach”, which was applied in 
India to develop medicines from Ayurvedic medicines 





Papers depicting the 




PEA is a food supplement with a well-stablished analgesic 
activity in animals. A BJP paper unveiled the molecular 
mechanism involved in PEA-induced analgesic effects by 
showing its ability to activate and desensitize TRPV1 in 
sensory neurons 
Ambrosino 
et al., 2013 
Papers depicting the 
mode of action of a 
major ingredient 







Extract from Petasites hybridus (butterbur) are used for 
migraine prevention. A BJP paper showed that a isopetasin, 
a major ingredient of butterbur, activated TRPA1 channels, 
resulting in excitation of neuropeptide-containing 
nociceptors, followed by marked heterologous neuronal 
desensitization.  
The Authors conclude that “such attenuation in pain and 
neurogenic inflammation [by isopetasin] may account for the 





old natural drugs 
Digoxin inhibited endothelial focal adhesion kinase and 
angiogenesis induced by different growth 
factors.  
The Authors conclude that “These novel findings suggest a 
potential repositioning of digitoxin as a broad-spectrum anti-
angiogenic drug for diseases where pathological 
angiogenesis is involved” 
Trenti et al., 
2017 
Papers related to 
naturally-occurring 
drugs of abuse 
A BJP paper investigated the involvement of the CRF2 
receptor in social dysfunction and stress vulnerability 
induced by repeated administration of cocaine and 
withdrawal from cocaine.  
The Authors conclude that “These findings demonstrate a 
central role for the CRF2 receptor in social behaviour 






Papers promoting a 
phytochemical as 
lead compound for 
the development of 
new medicines 
Novel tetracyclic triterpenoid compounds, isolated from the 
mushroom Poria cocos, were demonstrated to be effective 
against experimental renal fibrosis. 
The Author conclude that “Our results provide several 
potential leads for the development of 
novel compounds for effective treatment of chronic kidney 
disease” 
Wang et al., 
2018 
Papers in which a 
natural compound is 
used as a chemical 
probe to block or 
activate a specific 
target 
Acid-sensing ion channels (ASICs) are voltage-insensitive 
cation widely expressed in central and peripheral nerves. 
Peptide toxins from animal venoms, such as mambalgins, 
target different ASIC subtypes.  
 
In a BJP paper, mambalgin-1, a specific inhibitor of 
ASIC1a- and ASIC1b-containing channels, was used as a 
chemical probe to reveal the role of such channels in 




the effect of a 
natural compound 
with a related semi-
synthetic compound 
Dihydrodiosgenin, the parent aglycone of diosgenyl saponin, 
protected against pancreatic acinar cell against three 
clinically relevant models of experimental acute pancreatitis 





Papers reporting the 
effect of a naturally-
occurring molecule 
on specific targets 
(e.g. receptors, 
enzymes) 
The diterpene ester tonantzitlolone displayed nanomolar 
potency as an activator of transient receptor potential 






Ginkgo biloba extracts are widely promoted for conditions 
related to microcirculatory and memory deficits. A BJP 
paper delineated the pharmacokinetics of flavonols and 
terpene lactones (i.e. the main active ginkgo ingredients) 
after dosing standardized Ginkgo biloba leaf extracts to rats. 
Chen et al., 
2013 
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Papers promoting a 
natural compound 
for cosmetic use 
Kazinol U is a prenylated flavan isolated from the Chinese 
and Japanese plant Broussonetia kazinoki. A BJP paper 
showed that kazinol U reduced melanogenesis. 
The Authors conclude that “These findings indicate that 
kazinol U might be therapeutically and cosmetically applied 
for several hyperpigmentation skin disorders and skin 
whitening” 
 




supplement delivery  
Curcumin is a widespread dietary supplement whose clinical 
use is limited by the poor oral bioavailability. A BJP paper 
provided evidence that biodegradable nanosystems 












































Table 2. Authors checklist for manuscripts to be submitted to the British Journal of Pharmacology 
 Questions  Comment/Advice 
1 Is the mechanism of action of the 
natural product reported? 
BJP seeks to advance understandings of the 
mechanisms of action of pharmacological compounds 
2 Does the study report the activity 
of a mixture of compounds (e.g. 
herbal extracts) or a pure 
compound? 
BJP ordinarily does not publish papers on mixture of 
compounds unless the manuscript also demonstrates 
that any activity evidenced is reproduced by a purified 
component of that mixture.  
Purity must be evidenced and % stated 
3 What is the origin of the natural 
product? 
Methods must disclose source, extraction and 
purification/synthesis process  
4 Has the effect of the vehicle on the 
response under study been 
reported?  
Vehicle effects must be clearly reported, with mean ± 
SEM or SD?, appropriate statistical analysis and with 
n≥5. 
5 Has a positive control been used?  The effect of the compound under investigation should 
be compared with a clinically-effective drug. If the 
positive control has been not reported, include a valid 
scientific justification (e.g. there are no clinically-
effective drugs for the specific disease).  
Discuss the size of the effect in relation to the disease 
under evaluation. 
6 Are the concentrations used in vitro 
appropriate for further 





Rationale for the selection of concentrations used must 
be provided. Include a valid scientific justification if 
high concentrations (e.g. ≥25 µM) are used.  
 
Pharmacokinetic data on plasma levels following 
systemic administration should be reported.  
 
Concentrations much higher than the IC50 or Ki 
reported for the compound under investigation must 
not be used. 
7 Are the doses used in vivo relevant 
for translation?  
The rationale for the selection of the doses used must 
be provided. If testing as a potential therapeutic, 
relevance to the clinical setting must be provided.  
8 Is the dosing schedule appropriate? The rational for the selection of the route, timing and 
frequency of administration should be provided. 
to cure rather than to prevent (or vice versa).  
9 Is the compound under 
investigation safe? 
Evidence of safety should be provided, or if not 
available, discuss issues regarding potential toxicity.   
10 Are experimental design and 
analysis, data presentation and 
sharing in line with BJP 
guidelines? Has been sex 
considered as a biological variable?   
BJP guidelines must be adhered to, using Editorials as 
a reference (Curtis et al., 2018; George et al., 2017; 
George et al., 2019; Alexander et al., 2018; Docherty 
et al., 2019). Checklists are available on BJP website. 
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